LiveWell: A Mobile Intervention for Bipolar Disorder

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT03088462
Collaborator
National Institute of Mental Health (NIMH) (NIH)
205
2
2
48.7
102.5
2.1

Study Details

Study Description

Brief Summary

LiveWell is a study evaluating the use of smartphones to better understand and improve the treatment of bipolar disorder. Our goal is to increase access to psychosocial interventions and improve their effectiveness in reducing symptoms and preventing mood episodes.

Condition or Disease Intervention/Treatment Phase
  • Other: Psychiatric management
  • Behavioral: Psychosocial treatment
  • Behavioral: LiveWell Program
N/A

Detailed Description

A single blind, randomized controlled trial (N = 200, 2:3 ratio of usual care vs usual care and intervention) will be conducted in clinical practices around Chicago and Minneapolis. Eligible participants are adult bipolar 1 disorder patients not experiencing a current mood episode with a history of at least one acute episode in the last two years who are in treatment with a psychiatrist.

The primary clinical outcome will be time to relapse, and the secondary outcomes will be percent time symptomatic, symptom severity, and quality of life.

Participation in the study lasts for 12 months. Participants are asked to carry a smartphone with them whenever they leave home and wear a wristwatch for measuring activity all day every day. Participants are also asked to complete a series of telephone assessments and may be asked to complete daily check-ins on a smartphone and work with a health coach.

Participants will need to attend two in-person clinic visits at 680 N Lake Shore Drive, Chicago IL 60611 Suite 1520 or at 3311 E Old Shakopee Rd, Bloomington, MN 55425.

Study Design

Study Type:
Interventional
Actual Enrollment :
205 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
LiveWell: A Mobile Intervention for Bipolar Disorder
Actual Study Start Date :
Mar 20, 2017
Actual Primary Completion Date :
Apr 10, 2020
Actual Study Completion Date :
Apr 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Treatment As Usual

Any treatment for bipolar disorder participant is involved in.

Other: Psychiatric management
Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.

Behavioral: Psychosocial treatment
Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.

Experimental: Treatment As Usual + LiveWell Program

Treatment as usual combined with the LiveWell program.

Other: Psychiatric management
Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.

Behavioral: Psychosocial treatment
Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.

Behavioral: LiveWell Program
Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.

Outcome Measures

Primary Outcome Measures

  1. Longitudinal Interval Follow-up Evaluation-Clinical Monitoring Form: Clinical Status [Up to 48 weeks]

    Semi-structured interview designed to assess clinical status allowing determination of time to relapse (onset of a mood episode). Clinical Status: episode = depression, mania, hypomania, mixed; continued symptomatic (≥ 3 moderate symptoms without recovery), recovering (≤ 2 moderate symptoms, ≤ 8 weeks), prodromal (≥ 3 moderate symptoms after recovery); recovered (≤ 2 moderate symptoms, ≥ 8 weeks).

Secondary Outcome Measures

  1. Longitudinal Interval Follow-up Evaluation-Clinical Monitoring Form: Symptom Severity [48 weeks]

    Semi-structured interview designed to assess symptom severity allowing determination of percent time symptomatic (time with psychiatric status rating > 1.5). Psychiatric Status Rating: Syndromal Symptoms - 6 = definite criteria with psychotic symptoms or extreme impairment, 5 = definite criteria without psychotic symptoms or extreme impairment; Subsyndromal Symptoms - 4 = not definite criteria but major symptoms or major impairment, 3 = ≥ 3 moderate symptoms, moderate impairment, 2 = ≤ 2 moderate criteria symptoms, minimal impairment; Asymptomatic:1.5 = ≥ 1 mild but no moderate criteria symptoms; 1 = no mild or moderate criteria symptoms.

  2. Change in Quick Inventory of Depressive Symptomatology-Clinician Rating [At 0, 8, 16, 24, 32, 40 and 48 weeks]

    Structured interview designed to assess severity of depression. Scale range is from 0-27.

  3. Change in Young Mania Rating Scale [At 0, 8, 16, 24, 32, 40 and 48 weeks]

    Structured interview designed to assess severity of mania. Scale range is from 0-60.

  4. Change in World Health Organization Quality of Life Scale (BREF) [At 0, 24 and 48 weeks]

    Structured interview designed to assess physical health, psychological health, social relationships, and environment. Each domain is scored individually with transformed scores of 4-20.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults 18-65 years

  • Bipolar Disorder Type I

  • Minimum of 1 acute episode in the last 2 years

Exclusion Criteria:
  • Not receiving psychiatric care

  • Current mood episode

  • Current substance use disorder (within the last 3 months)

  • Current severe suicidal ideation or a recent serious suicide attempt (within the last 3 months)

  • Inability to speak and read English

  • Visual, hearing, voice, cognitive or motor impairment that would prevent completion of study and treatment procedures

Participants will need to attend two in-person clinic visits at 680 N Lake Shore Drive, Chicago IL 60611 Suite 1520 or at 3311 E Old Shakopee Rd, Bloomington, MN 55425.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Chicago Illinois United States 60611
2 HealthPartners Institute Bloomington Minnesota United States 55425

Sponsors and Collaborators

  • Northwestern University
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Evan H Goulding, MD/PhD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Evan Goulding, Assistant Professor, Department of Psychiatry and Behavioral Sciences, Northwestern University
ClinicalTrials.gov Identifier:
NCT03088462
Other Study ID Numbers:
  • 1R01MH110626
  • 1R01MH110626
First Posted:
Mar 23, 2017
Last Update Posted:
Oct 4, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Evan Goulding, Assistant Professor, Department of Psychiatry and Behavioral Sciences, Northwestern University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2021